The estimated Net Worth of Martin Indyk is at least $4.08 million dollars as of 5 June 2024. Mr. Indyk owns over 20,000 units of MeiraGTx plc stock worth over $145,600 and over the last 6 years he sold MGTX stock worth over $0. In addition, he makes $3,931,860 as Independent Director at MeiraGTx plc.
Martin has made over 2 trades of the MeiraGTx plc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of MGTX stock worth $83,200 on 5 June 2024.
The largest trade he's ever made was exercising 20,000 units of MeiraGTx plc stock on 5 June 2024 worth over $83,200. On average, Martin trades about 5,833 units every 61 days since 2019. As of 5 June 2024 he still owns at least 35,000 units of MeiraGTx plc stock.
You can see the complete history of Mr. Indyk stock trades at the bottom of the page.
Martin Indyk Ph.D. serves as Independent Director of the Company. He is an American diplomat who has served in senior positions in the Clinton, George W. Bush and Obama administrations, including at the U.S. Department of State as a Special Envoy for Israeli-Palestinian Negotiations and as the U.S. Ambassador to Israel. Since October 2018, Mr. Indyk has served as a Distinguished Fellow and Director of Executive Education at the Council on Foreign Relations, a non-profit think tank specializing in U.S. foreign policy and international affairs. Prior to his current role, from 2010 to 2018, Mr. Indyk worked at The Brookings Institution, a non-profit public policy organization, where he was responsible for raising and managing funding for the organization. At The Brookings Institution, he served as the John C. Whitehead Distinguished Fellow in International Diplomacy from 2017 to 2018 and as Executive Vice President from 2015 to 2017. Mr. Indyk has also served at the U.S. Department of State as a Special Envoy for Israeli-Palestinian Negotiations and as the U.S. Ambassador to Israel. Since 2003, Mr. Indyk acted as Co-Founder with Sheikh Hamad bin Jassem al-Thani of the Doha Forum on U.S. Relations with the Islamic World and, from 2004 to 2017, Mr. Indyk acted as Co-Founder with Haim Saban of the Saban Forum on U.S.-Israel Relations. Mr. Indyk also serves on the boards of several non-profit organizations. Mr. Indyk received a Bachelor of Economics (with honors) from the University of Sydney and a Ph.D. in international relations from the Australian National University.
As the Independent Director of MeiraGTx plc, the total compensation of Martin Indyk at MeiraGTx plc is $3,931,860. There are 3 executives at MeiraGTx plc getting paid more, with Alexandria Forbes having the highest compensation of $8,480,260.
Martin Indyk is 68, he's been the Independent Director of MeiraGTx plc since 2019. There are 3 older and 14 younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.
Martin's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.
Over the last 6 years, insiders at MeiraGTx plc have traded over $7,031,523 worth of MeiraGTx plc stock and bought 9,222,038 units worth $85,317,799 . The most active insiders traders include Advisors Llcperceptive Life..., Joel S Marcus et Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of $672,044. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth $5,000,000.
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
MeiraGTx plc executives and other stock owners filed with the SEC include: